导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.73% | 1563/4773 |
| 近一周 | -0.40% | 1051/5465 |
| 近一月 | -1.91% | 1373/5421 |
| 近一季 | -7.63% | 2902/5231 |
| 近半年 | -3.86% | 2625/4920 |
| 近一年 | 10.27% | 1125/4394 |
| 近两年 | 70.88% | 1002/2954 |
| 近三年 | 43.66% | 676/2253 |
| 成立以来 | 157.75% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.28% 1330/4961 |
14.09% 1875/5312 |
- - |
- - |
| 2025 | 30.71% 1299/4813 |
1.15% 1687/3635 |
4.98% 670/4076 |
18.29% 2320/4524 |
4.05% 576/4813 |
| 2024 | 9.09% 1495/3463 |
0.11% 1039/2808 |
-3.13% 1303/3014 |
11.62% 2490/3129 |
0.78% 1168/3463 |
| 2023 | 2.77% 304/2656 |
9.02% 432/2280 |
-1.06% 438/2385 |
-2.00% 611/2515 |
-2.78% 529/2655 |
| 2022 | -10.76% 218/2207 |
-12.63% 642/1919 |
3.81% 1085/2016 |
-6.21% 98/2113 |
4.90% 504/2208 |
| 2021 | 29.56% 72/1822 |
8.54% 63/1255 |
14.65% 247/1330 |
2.68% 431/1466 |
1.40% 947/1822 |
| 2020 | - - |
- - |
- - |
14.25% 287/1164 |
4.10% 869/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏中证500指数增强C VS. 长安沪深300非周期A(740101) |